CCR5 and HIV infectious disease: CCR5 (Xu et al., 2014) and CXCR4 (De Clercq, 2010) antagonists are on the market for the treatment of CCR5-tropic HIV infection and to promote mobilization of hematopoietic stem cells in transplant patients, respectively.